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ABSTRACT  
In recent times drastic changes have taken place in dietary habits and mode of 
life style which has resulted in precipitation of various metabolic diseases. One 
such alarming condition, which is on a high rise in the society, is Dyslipidemia. 
Since the pathology has a clear link with a person’s life style, the body demands 
a more holistic approach in treatment, hence indigenous system of medicine 
especially herbal preparations can play major role in finding a safe, simple and 
cost effective solution for the management of Dyslipidemia. Shigru botanically 
identified as Moringa oleifera Lam. is one of such commonly available plant 
which is greatly praised for its Medoghna property in various Nighantus. 
A clinical study of Shigru twak (stem bark) was conducted on 30 patients at 
OPD level of Government Ayurveda College Hospital, Tripunithura, Kerala. 
Shigru stem bark powder (Choornam) was given in the form of capsule, in a 
dose of 3gm per day along with lukewarm water before food for a period of 45 
days. Assessment based on blood lipid levels and clinical features was done 
before and after treatment. The results were statistically analyzed. After the 
intervention Total Cholesterol, Serum LDL, Serum VLDL, Serum Triglyceride 
and Body weight were significantly reduced. On symptomatic evaluation the 
drug was significantly effective in reducing heaviness of body, chest pain, 
excessive sleep, excessive sweating, and breathlessness on exertion, palpitation 
and lethargy. The study revealed that Shigru twak is safe and effective in 
Dyslipidemia. 
INTRODUCTION
 Ayurveda is an eternal science playing a 
key role in the treatment of many incurable, chronic 
diseases and even minor ailments which are hampering 
the excellence of life. The present era is immensely 
occupied by disarray, stress and strain due to lifestyle 
modification, changes in dietary habits and urbanization. 
This has led to the upsurge of various metabolic diseases 
such as Diabetes, Hypertension, Hyperlipidemia, Cardio 
vascular diseases etc. One such alarming condition, 
which is on a high rise in the society, is Dyslipidemia. 
According to World Health Organisation (WHO) almost 
one fifth (18%) of global stroke events and about 56% of 
Global Heart diseases are attributed to Hyperlipidemia. 
This is responsible for about 4.4 million deaths (7.9% of 
total) and 2.8% of global disease burden1. Dyslipidemia 
has been found to be one of the most important 
contributing factors for Cardio vascular disease (CAD) 
which is the most prevalent cause of death and disability 
in both developed and developing countries2. 
The etiology and pathogenesis of Dyslipidemia, 
to a great extent is alike the Nidana and Samprapti of 
Medoroga. The causes of Dyslipidemia like junk and fatty 
food, sedentary life style etc. are much similar to Ati 
snigdha, Guru, Picchila ahara sevana and Cheshta dvesha 
which leads to Medoroga and Medo Vridhi. In addition 
being a metabolic syndrome, there is a definite relation 
between pathophysiology of Dyslipidemia with the 
Agnivaigunya at different levels, starting from Jatharagni 
up to Dhatvagni. Ayurveda as well considers Agni vikriti 
as the root cause of Medoroga. Accordingly we can say 
that the most similar condition which can be put side by 
side to Dyslipidemia is Medoroga. 
Shigru is a commonly available plant cultivated 
all over India. Its leaves and fruits (pods) are used in 
preparation of food. In Ayurveda it has been mentioned 
as a common ingredient in various formulations for 
Sthula chikitsa by Acharya Charaka3 and Acharya 
Vagbhata4. According to Ayurveda Pharmacopoeia of 
India, Moringa oleifera Lam. belonging to Moringaceae 
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family is the botanical source of Shigru. Experimental 
studies have proved its Anti Hypertensive, 
Hypocholesteromic, Anti ulcer and Wound healing 
properties5-8. It is also established that the aqueous 
extract of Moringa oleifera Lam. stem bark is significant 
to reduce the levels of cholesterol, triglycerides, VLDL 
and LDL and to increase the level of HDL9. 
Based on the above references Shigru (Moringa 
oleifera Lam.) can be considered as a beneficial drug in 
Dyslipidemia. Hence this study has been undertaken to 
evaluate the effect of stem bark powder of Shigru 
(Moringa oleifera Lam.) in Dyslipidemia. 
Considering its greater prevalence and need for 
the search of a cost effective alternative medicine that 
can prevail over Dyslipidemia with no side effects, this 
study has been taken. 
Objectives of the study 
 To evaluate the efficacy of stem bark powder of 
Shigru (Moringa oleifera Lam.) in Dyslipidemia. 
MATERIALS AND METHODS 
Sample: The patients (samples), coming under the 
inclusion criteria, were randomly selected for the study 
from the OP units of the Dept. of Dravyaguna and other 
Departments of Govt. Ayurveda College Hospital, 
Tripunithura.  
Sample frame 
a. Study design: Single arm, Randomized, 
Interventional, Quasi-experimental 
b. Sample size :  30  
c. Study duration: 18 months 
d. Selection of patients: As per inclusion and 
exclusion criteria 
e. Study setting: Govt. Ayurveda College Hospital, 
Tripunithura, Kerala 
Inclusion criteria 
a. Patient of both sexes having any one or all of the 
following altered lipid levels will be selected. (ATP III 
Guidelines, NCEP) 
 Total cholesterol above 200mg/ dl  
 LDL cholesterol above 130mg/dl 
 HDL cholesterol below 40 mg/dl 
 Triglycerides above 150mg/dl  
b. Age group- 20 – 70 years  
c. Patient willing to give written informed consent. 
 Exclusion criteria 
a. Patient below 20 years and above 70 years. 
b. Patient having serious Cardiac disorders like MI, 
Cardiac failure etc. 
c. Severe Hepatic disorders, Renal insufficiency  
d. Pregnant and lactating females  
e. Patient having history of untreated Thyroid 
disorders  
f. Uncontrolled Diabetes mellitus  
g. Patients taking any other form of medication for 
Dyslipidemia. 
h. Any other condition that may jeopardize the study. 
 
Drug preparation 
1. Study drug: The drug used in the study was Shigru 
twak churna (stem bark powder of Moringa oleifera 
Lam.). 
2. Collection of raw materials: The study drug, stem 
bark of Shigru (Moringa oleifera Lam.) was collected 
from the open market and was pharmacognostically 
identified.  
3. Preparation of medicine: Stem bark of Shigru 
(Moringa oleifera Lam.) was checked for earthly and 
foreign matter, allowed to dry in shade. After attaining 
proper dryness the drug was made into fine powder of 
mesh size-120. Then this powdered drug was filled into 
500mg capsules. 
Dose and mode of administration 
The dose was fixed as per Ayurveda 
Pharmacopoeia of India. The patients were advised to 
take 3 gm of Shigru twak churna (2 capsules thrice a day, 
i.e. 1gm drug thrice a day) along with lukewarm water 
before food for a continuous period of 45 days. 
Table 1: Treatment Schedule 
Particulars Details 
Sample size 30 
Drug Shigru twak churna 
Form of 
medication 
Capsule 
Dose 3gm (2 capsules thrice a day, i.e. 
1gm drug thrice a day) 
Anupana Luke warm water 
Duration 45 days 
Assessment Criteria 
The patients were assessed mainly on the investigation 
of fasting lipid levels like 
 Serum total cholesterol. 
 Serum low density lipoprotein. 
 Serum very low density lipoprotein. 
 Serum high density lipoprotein.  
 Serum triglycerides. 
These were assessed before taking drug, on 15th 
& 30th day and after the completion of intervention (i.e. 
on 45th day). Changes in subjective symptoms like 
palpitation, chest pain, and heaviness of body, 
breathlessness on exertion, excessive sleep, excessive 
sweating and lethargy were evaluated before and after 
treatment. The change in the body weight was also 
assessed on 1st day and after completion of intervention. 
Follow up  
A follow up was done for three months, all 
patients were advised to come to OPD at regular interval 
of 1 month after study period, but in case of any feeling 
of discomfort they were advised to come to OPD at any 
time. Both subjective and objective data were collected 
from patients at regular intervals and were documented. 
Ethical considerations 
An informed consent was obtained from all patients 
before trial. The conditions of informed consent were 
fully carried out and autonomy of the patients was given 
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utmost respect. Approval from Institutional Ethical 
Committee was also obtained and the details of the study 
were also informed to the committee periodically. 
Results and Discussion  
 The information gathered on the basis of above 
observations was subjected to statistical analysis using 
suitable statistical tools. Arithmetic mean (AM), standard 
deviation (SD), mean difference (MD), frequencies and 
percentages were used for summarizing the collected 
data. Paired ‘t’ test was applied for the objective 
parameters which are measured on an interval scale to 
analyze the before –after effect of therapy of respective 
parameters. Chi square test was carried out for 
subjective criteria to analyze the before –after effect of 
therapy of respective parameters. 
1. Effectiveness of treatment on clinical symptoms 
Table 2: Effectiveness of treatment on clinical symptoms 
Symptom BT AT Chi square P value 
N % N % 
Palpitation 18 60 8 26.67 6.780 <0.05 
Chest pain 12 40 5 16.67 4.020 <0.05 
Breathlessness on exertion 18 60 9 30 5.450 <0.01 
Excessive sleep 15 50 6 20 5.930 <0.01 
Excessive sweat 12 40 5 16.67 4.020 <0.05 
Heaviness of body 21 70 7 23.33 13.12 <0.001 
Lethargy 18 60 6 20 10.00 <0.001 
 
Graph 1: Effectiveness of treatment on Clinical symptoms 
 Chi square analysis showed that reduction in symptoms like palpitation, chest pain and excessive sweating was 
statistically significant (p<0.05). Effectiveness of the drug on breathlessness on exertion and excessive sleep was also 
found to be statistically highly significant (p<0.01). Also there was a marked reduction in symptoms like heaviness of 
body and lethargy and it was found to be highly significant (p<0.001).  
2. Evaluation of the effectiveness of interventions on Blood parameters 
Table 3: Effectiveness of treatment on total cholesterol 
Stage Mean SD N Group Mean difference Paired ‘t’ P 
BT 260.26 39.708 30 BT Vs 15th 30.766 1.198 >0.05 
15th day 229.50 38.884 30 BT Vs 30th 10.6 3.779 <0.001 
30th day 218.90 31.772 30 BT Vs AT 14.8 4.319 <0.001 
AT 204.10 30.465 30  
Graph 2: Analysis of effect of treatment on Total Cholesterol 
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 Total cholesterol was analyzed before 
intervention, on 15th day, 30th day and after intervention. 
Considering the changes in total cholesterol values 
before treatment and on the 15th day reduction of 30.766 
was observed in mean which was statistically not 
significant (p>0.05).  
On evaluating the total cholesterol values before 
treatment and on 30th day of intervention reduction in 
mean was 10.6 which was highly significant (p<0.001). 
Analyzing total cholesterol values before and after 
intervention mean difference observed was 14.8 and the 
reduction was found to be highly significant (p<0.001). 
3. Effectiveness of treatment on LDL cholesterol  
Table 4: Effectiveness of treatment on LDL cholesterol 
Stage Mean SD N Group Mean difference Paired ‘t’ P value 
BT 174.73 40.994 30 BT Vs 15th 23.80 0.0001 >0.05 
15th day 150.93 43.811 30 BT Vs 30th 12.83 2.7248 <0.05 
30th day 138.10 34.042 30 BT Vs AT 9.769 3.9120 <0.001 
AT 130.33 40.025 30  
 
Graph 3: Analysis of effect of treatment on LDL 
 On analyzing the changes in LDL values before treatment and on the 15th day, reduction observed in mean was 
23.80 which was statistically not significant (p>0.05). On evaluating LDL values before treatment and on 30 th day of 
intervention, mean difference of 12.83 was observed which was statistically significant (p<0.05). Analyzing LDL values 
before and after intervention, the mean difference of 9.769 was observed and the reduction was found to be highly 
significant (p<0.001). 
4. Effectiveness of treatment on HDL cholesterol  
Table 5: Effectiveness of treatment on HDL cholesterol 
Stage Mean SD N Group Mean difference Paired ‘t’ P 
BT 44.40 9.015 30 BT Vs 15th 2.360 0.0264 >0.05 
15th day 46.76 8.045 30 BT Vs 30th 0.270 0.0303 >0.05 
30th day 47.03 8.256 30 BT Vs AT 2.470 0.0010 >0.05 
AT 49.50 9.694 30  
 
Graph 4: Analysis of effect of treatment on HDL 
 On analyzing the changes in HDL values before treatment and on the 15th day, an increase of 2.36 was 
observed in mean which was statistically not significant (p>0.05). On evaluating HDL values before treatment and on 
30th day of intervention, an increase of 0.27 was observed in mean, but it was statistically not significant (p>0.05). 
Analyzing HDL values before and after intervention, an increase of 2.47 was observed in mean, which was also 
statistically not significant (p>0.05). 
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5. Effectiveness of treatment on VLDL cholesterol  
Table 6: Effectiveness of treatment on VLDL cholesterol 
Stage Mean SD N Group Mean difference Paired ‘t’ P 
BT 41.066 19.592 30 BT Vs 15th 3.80 0.0177 >0.05 
15th day 37.266 18.192 30 BT Vs 30th 0.60 0.0152 >0.05 
30th day 36.666 20.672 30 BT Vs AT 4.70 2.9844 <0.01 
AT 31.966 13.296 30  
 
Graph 5: Analysis of effect of treatment on VLDL 
 Considering the changes in VLDL values before treatment and on the 15th day, reduction observed in mean was 
3.80, which was statistically not significant (p>0.05). On evaluating VLDL values before treatment and on 30 th day of 
intervention, reduction observed in mean was 0.60, but it was statistically not significant (p>0.05). Analyzing VLDL 
values before and after intervention mean difference observed was 4.70 and the reduction was found to be statistically 
highly significant (p<0.01). 
6. Effectiveness of treatment on Triglyceride 
Table 7: Effectiveness of treatment on Triglyceride 
Stage Mean SD N Group Mean difference Paired ‘t’ P value 
BT 200.16 98.293 30 BT Vs 15th 16.10 0.0248 >0.05 
15th day 184.06 87.348 30 BT Vs 30th 0.67 0.0196 >0.05 
30th day 184.73 102.08 30 BT Vs AT 26.47 6.6776 <0.001 
AT 158.26 79.023 30  
 
Graph 6: Analysis of effect of treatment on Triglyceride 
 Considering the changes in triglyceride values, before treatment and on the 15th day, reduction observed in 
mean was 16.10, which was statistically not significant (p>0.05). On evaluating triglyceride values before treatment 
and on 30th day of intervention, reduction observed in mean was 0.67, but it was statistically not significant (p>0.05). 
Analyzing triglyceride values before and after intervention, mean difference observed was 26.47 and the reduction was 
found to be highly significant (p<0.001). 
7. Effectiveness of treatment on Haemoglobin 
Table 8: Effectiveness of treatment on Haemoglobin 
Stage Mean SD N Mean Difference Paired ‘t’ P 
BT 11.84 2.029 30 
1.12 1.0285 0.6663 
AT 12.96 1.824 30 
 
 
0
10
20
30
40
50
BT 15th day 30th day AT
M
ea
n
 v
a
lu
e 
o
f 
V
L
D
L
0
50
100
150
200
250
BT 15th day 30th day AT
M
ea
n
 v
a
lu
e 
o
f 
T
ri
g
ly
ce
ri
d
e 
 Parul Singh et al. Evaluation of Stem Bark Powder of Shigru (Moringa Oleifera Lam.) in Dyslipidemia 
AYUSHDHARA | January - February 2016 | Vol 3 | Issue 1  450 
 
Graph 7: Analysis of effect of treatment on Haemoglobin 
On analysis the effectiveness on haemoglobin the difference in mean was 1.12 and it was statistically not 
significant in increasing the Haemoglobin (p>0.05). 
8. Effectiveness of treatment on Total Leucocyte Count  
Table 9: Effectiveness of treatment on Total Leucocyte Count 
Stage Mean SD N Mean Difference Paired ‘t’ P value 
BT 8325 1130.4 30 
20 0.5247 0.6058 
AT 8345 1051.6 30 
 
Graph No.8 Analysis of effect of treatment on TLC 
On analyzing the changes in Total Leucocyte Count value, an increase of 20 was observed in mean which was 
statistically not significant for increasing Total Leucocyte Count (p>0.05). 
9. Effectiveness of treatment on FBS 
Table 9: Effectiveness of treatment on FBS 
Stage Mean SD N Mean Difference Paired ‘t’ P 
BT 108.9 11.756 30 
2.2 2.152 0.0445 
AT 106.7 8.189 30 
 
Graph 8: Analysis of effect of treatment on FBS 
On analyzing the changes in FBS reduction of 2.2 observed in mean which was statistically significant (p<0.05) 
for reduction in FBS level. 
10. Evaluation of the efficacy and comparison of intervention on body weight 
Table 10: Effectiveness of treatment on body weight 
Stage Mean SD N Mean Difference Paired ‘t’ P value 
BT 66.33 10.94 30 
4.63 9.976 <0.05 
AT 61.70 9.97 30 
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Graph 9: Analysis of effect of treatment on Body weight 
On comparing body weight before and after 
treatment reduction of 4.63 was observed in mean which 
was statistically significant (p<0.05) 
DISCUSSION 
Shigru as the name implies that which is Tikshna 
in nature; is endowed with the properties like Tikta, Katu 
rasas, Laghu, Ruksha, Tikshna gunas, Ushna veerya and 
Katu vipaka. 
Tikta rasa is having the properties Agni deepana, 
Ama pachana, Lekhana and Kleda-meda-vasa-majja-
sweda upshoshana. Katu rasa possess properties like Agni 
deepana, Ama pachana, Sroto vivarana (dilating Srotas), 
Shodhana, Lekhana, Srotobandha bhedana (removing 
obstruction in the Srotas) and Kleda-meda vishoshana. 
Sroto vivarana and Lekhana property of Katu rasa has 
direct action on Srotas; thereby clearing the Srotosanga 
and dilating the body channels; thus providing proper 
nourishment to the Dhatus, which was previously 
hampered by the blocked Srotas. Also Katu rasa is having 
the property of Kleda meda vishoshana and Kapha 
samana. In Medoroga, Meda Dhatu is increased; here 
Katu rasa owing to its Kleda-meda vishoshana property 
causes Vishoshana of Medo dhatu and thus alleviates the 
excess Meda. Thus, both the Rasas in Shigru plays vital 
role in Samprapti vighatana of Medoroga through Agni 
deepana, Ama pachana, Kapha shamana and Meda 
vishoshana properties. Laghu and Ruksha guna exhibits 
their action through Samanya- Vishesha sidhanta to 
reduce guru and Snigdha guna of Ama and Medo dhatu. 
Constriction in Srotas is relieved through Laghu, ruksha 
and Tikshna guna. Furthermore Tikshna guna is 
responsible for cleaning action of body channels and fast 
action of the drug. Main Dosha vitiated in Medoroga is 
Kapha and Vata. Ushna virya of Shigru pacifies the 
vitiated Vata and also alleviates Kapha dosha. Moreover 
it is Agni Vardhaka and Pachaka therefore corrects the 
vitiated Agni and alleviates the Ama. 
At Dhatu level due to Medoshoshana property of 
Katu, Tikta rasa and Laghu, Ruksha guna, the drug brings 
down the increased Medodhatu to normalcy. On 
considering the drug action on Srotas due to 
srotoshodhaka and Lekhana property of Katu and tikta 
rasa, and Gunas like- Laghu, Ruksha and Teekshna; it 
removes Srotorodha. As well as owing to its Laghu guna 
it goes through the minute Srotas. Also due to its 
Teekshna guna the drug action is prompt.  
Considering the action of Shigru on Agni; its Agni 
deepana property, Laghu and Teekshna guna will 
alleviate the vitiated Jatharagni and Dhathavagni. As a 
result of this Dhatu nirmana process gets normal up and 
this ultimately leads to their proper formation. The Ama 
Pachana property of its rasa (Katu, Tikta rasa) and Guna 
(Laghu and Ruksha) will alleviate Ama, which is also the 
root cause of Medoroga. 
Thus Shigru is vital in Samprapti vighatana of 
Medoroga owing to its Tikta, Katu rasas, Laghu, Ruksha, 
Tikshna gunas, Ushna veerya and Katu vipaka. 
 Experimental researches have also proved that 
Shigru (Moringa oleifera Lam.) decreases Total 
cholesterol and Triglyceride level by increasing activity 
of extra hepatic lipoprotein lipase10 which is responsible 
for circulating lipoprotein in a non atherogenic direction 
by efficient lipogenesis of triglyceride rich lipoprotein in 
heart, skeletal muscle and adipose tissue11. β-sitosterol 
was isolated from the stem of Moringa oleifera Lam12-13. 
It is a plant sterol and is believed to lower cholesterol by 
lowering plasma concentrations of LDL14. Also it inhibits 
the reabsorption of cholesterol and thus increases its 
excretion into faeces (in the form of neutral steroids) 
that results in decrease of body lipids15. 
Accordingly from the above symposium on the 
Rasapanchaka; it can be concluded that the drug Shigru 
substantially shows Medohara property (antihyper-
lipidemic activity) and is competent in treatment of 
Dyslipidemia. Experimental researches also prop up its 
antihyperlipidemic and antioxidant activities; which 
confirms that it can be utilized as an efficient drug for 
Dyslipidemia. Hence Shigru is having all the 
pharmacological properties for the treatment of 
Medoroga.  
Thus the present study reveals that, there is a 
significant difference in clinical and biochemical 
parameters of Dyslipidemia patient before and after 
receiving Shigru twak choorna. So it can be said that 
Shigru twak has shown noteworthy efficacy in reducing 
serum lipid levels and clinical symptoms. At the same 
time through the observation it is exceedingly apparent 
that the drug showed even far better results in reducing 
the objective and subjective parameters when taken for 
longer duration.  
CONCLUSION 
On the basis of this study it can be concluded 
that, Dyslipidemia to some exposure can be considered 
as a sharing out of Medoroga, specifically as Medo dhatu 
vriddhi. Vata-kapha prakriti individuals are seen to be 
more affected by Dyslipidemia. Patients treated with 
Shigru twak showed that there was a significant decrease 
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in S. Cholesterol, S. LDL, S. VLDL, S. Triglycerides, FBS 
and body weight. Though the test drug Shigru twak was 
significantly not effective in increasing the HDL 
cholesterol level but there was a considerable increase in 
it; may be a prolong use of the drug can be helpful in 
escalating the S. HDL level up to a significant level. Also 
no adverse effect was observed during the clinical study. 
The results shown by drug Shigru (Moringa oleifera 
Lam.) can be attributed to its Katu, Tikta Rasa, Laghu- 
Ruksha, Teekshna Guna, Ushna veerya, Katu Vipaka and 
Kapha-vata shamana properties.  
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